Handelsbanken Fonder AB Sells 21,828 Shares of Hologic, Inc. (NASDAQ:HOLX)

Handelsbanken Fonder AB lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 10.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 192,405 shares of the medical equipment provider's stock after selling 21,828 shares during the period. Handelsbanken Fonder AB owned about 0.09% of Hologic worth $11,885,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Venturi Wealth Management LLC lifted its stake in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares during the last quarter. Smithfield Trust Co boosted its stake in shares of Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 400 shares in the last quarter. Finally, Raiffeisen Bank International AG acquired a new position in shares of Hologic during the 4th quarter valued at about $49,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Price Performance

NASDAQ HOLX traded down $0.47 on Friday, hitting $64.75. The stock had a trading volume of 2,309,387 shares, compared to its average volume of 2,308,409. The firm has a 50-day moving average of $58.58 and a 200-day moving average of $65.05. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The company has a market capitalization of $14.43 billion, a price-to-earnings ratio of 20.43, a price-to-earnings-growth ratio of 2.14 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the company posted $1.03 EPS. Hologic's quarterly revenue was down 1.2% compared to the same quarter last year. Equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling

In other news, Director Martin D. Madaus bought 5,445 shares of the company's stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the purchase, the director now owns 5,445 shares in the company, valued at approximately $300,781.80. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.88% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on HOLX. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Argus lowered Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Stephens cut their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Royal Bank of Canada lowered their price objective on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Finally, Citigroup dropped their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Twelve research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $77.42.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.